PROF
Profound Medical Corp. (NASDAQ)
Healthcare — Medical Devices
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
Price History
Fundamentals
| Market Cap | $245.28M |
| P/E Ratio (TTM) | - |
| Forward P/E | -8.98 |
| EPS (TTM) | $-1.24 |
| Dividend Yield | - |
| Profit Margin | -206.76% |
| Revenue Growth | 103.60% |
| ROE | -70.59% |
| Debt/Equity | 12.56 |
| Recommendation | None |
| Analyst Target | $11.14 |
| Analysts | 5 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 51.3 |
| Beta | 0.52 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $8.95 |
| 52-Week Low | $3.76 |
| 50-Day Avg | $6.79 |
| 200-Day Avg | $6.56 |
| Avg Volume | 73.7K |
| Volume | 35.6K |
Performance Analysis
NEUTRALPROF presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:27 UTC
Back to Screener Export Report